Page 14 - Poster Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium ... Arch Therapeutics, Inc.May 10, 2021 GMT FRAMINGHAM, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, presents two clinical case reports supporting the broad potential of AC5 ® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced ...

PYC Therapeutics Announces Two Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting PYC's PPMO Technology Demonstrates Strong Potential to Overcome Critical Delivery Challenges and Reach Deepest Layers of Retina in Patient-Derived Models Modulation of Gene Expression to Upregulate PRPF31 and Rescue Retinitis Pigmentosa Type 11 Disease Phenotypes Achieved in Patient-Derived Models News provided by Share this article Share this article NEW YORK and PERTH, Australia, May 4, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology compa...

Search jobs 30-Apr-2021 Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting   SYDNEY, AUSTRALIA – 29 April 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and...

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting April 27, 2021 17:47 ET | Source: Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc. Novato, California, UNITED STATES NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its ...

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeli...